Tech Company Financing Transactions
iOnctura Funding Round
iOnctura, operating out of Genève, secured $18.6 million from European Innovation Council Fund.
Transaction Overview
Company Name
Announced On
12/21/2022
Transaction Type
Venture Equity
Amount
$18,580,000
Round
Undisclosed
Investors
European Innovation Council Fund (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its clinical program for IOA-289, an autotaxin inhibitor for the treatment of cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Campus Biotech Innovation Park Avenue Sécheron 15
Genève, 1202
CH
Genève, 1202
CH
Phone
Undisclosed
Website
Email Address
Overview
Founded in June 2017, iOnctura is a clinical stage biopharmaceutical company focused on delivering innovative cancer treatments to patients with unmet medical need. iOnctura is uncovering the key to unlock difficult to treat tumors burdened by stroma and immune mediated resistance. We do this by simultaneously targeting multiple tumor survival mechanisms with a single drug, disrupting the dynamic interplay at the heart of the tumor-stroma-immune interface.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Catherine Pickering
Chief Financial Officer
David SEEBERGER
Chief Marketing Officer
Michael LAHN
Chief Technical Officer
Lars Veen
Browse more venture capital transactions:
Prev: 12/21/2022: Treblle venture capital transaction
Next: 12/21/2022: Carallel venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs